MX2020002542A - Variantes de interleucina-18 y metodos de uso. - Google Patents

Variantes de interleucina-18 y metodos de uso.

Info

Publication number
MX2020002542A
MX2020002542A MX2020002542A MX2020002542A MX2020002542A MX 2020002542 A MX2020002542 A MX 2020002542A MX 2020002542 A MX2020002542 A MX 2020002542A MX 2020002542 A MX2020002542 A MX 2020002542A MX 2020002542 A MX2020002542 A MX 2020002542A
Authority
MX
Mexico
Prior art keywords
methods
interleukin
variants
activator
therapeutic
Prior art date
Application number
MX2020002542A
Other languages
English (en)
Inventor
Aaron Ring
Ting Zhou
Suzanne Fischer
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of MX2020002542A publication Critical patent/MX2020002542A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona composiciones y métodos que comprenden un activador de la actividad de IL-18 para uso en aplicaciones terapéuticas y no terapéuticas; el activador proporciona actividad de señalización de IL-18 incluso en presencia de una molécula inhibidora como IL-18BP.
MX2020002542A 2017-09-06 2018-09-06 Variantes de interleucina-18 y metodos de uso. MX2020002542A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762554605P 2017-09-06 2017-09-06
US201862652279P 2018-04-03 2018-04-03
PCT/US2018/049648 WO2019051015A1 (en) 2017-09-06 2018-09-06 VARIANTS OF INTERLEUKIN-18 AND METHODS OF USE

Publications (1)

Publication Number Publication Date
MX2020002542A true MX2020002542A (es) 2020-07-20

Family

ID=65517760

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002542A MX2020002542A (es) 2017-09-06 2018-09-06 Variantes de interleucina-18 y metodos de uso.

Country Status (12)

Country Link
US (4) US20190070262A1 (es)
EP (1) EP3678681A4 (es)
JP (2) JP2020533301A (es)
KR (1) KR20200066623A (es)
CN (1) CN111315395A (es)
AU (2) AU2018330444B2 (es)
BR (1) BR112020004389A2 (es)
CA (1) CA3080492A1 (es)
IL (2) IL305370A (es)
MX (1) MX2020002542A (es)
SG (1) SG11202001384TA (es)
WO (1) WO2019051015A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022014239A (es) * 2020-05-12 2023-02-09 Regeneron Pharma Nuevos agonistas de il10 y metodos para su uso.
AR123978A1 (es) * 2020-11-02 2023-02-01 Simcha Il 18 Inc Variantes de la interleucina-18 y métodos de uso
JPWO2022172944A1 (es) * 2021-02-10 2022-08-18
WO2023010021A1 (en) 2021-07-27 2023-02-02 Xencor, Inc. Il-18-fc fusion proteins
JP2023024168A (ja) 2021-08-06 2023-02-16 国立大学法人 長崎大学 がんの治療剤
WO2023114829A1 (en) 2021-12-15 2023-06-22 Genentech, Inc. Stabilized il-18 polypeptides and uses thereof
WO2023118497A1 (en) * 2021-12-22 2023-06-29 Pieris Pharmaceuticals Gmbh Novel il-18 variants
US20230357342A1 (en) * 2022-02-23 2023-11-09 Bright Peak Therapeutics Ag Modified il-18 polypeptides
US20240116997A1 (en) 2022-02-23 2024-04-11 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
WO2023161854A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2023215834A1 (en) * 2022-05-05 2023-11-09 Hospital Espanol Auxilio Mutuo De Puerto Rico, Inc. Methods for treating bladder cancer
WO2024031046A2 (en) * 2022-08-05 2024-02-08 Fuse Biotherapeutics Inc. Il-18 fusion proteins and methods of producing il-18
WO2024044780A1 (en) * 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
WO2024051728A1 (en) * 2022-09-06 2024-03-14 I-Mab Biopharma Co., Ltd. Il-18 variant polypeptides
WO2024086852A1 (en) * 2022-10-21 2024-04-25 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
US20240166705A1 (en) 2022-11-07 2024-05-23 Xencor, Inc. Il18-fc fusion proteins
CN118141897A (zh) 2022-12-07 2024-06-07 广州威溶特医药科技有限公司 Dr-18和溶瘤痘苗病毒在制备抗肿瘤药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6060283A (en) * 1996-06-27 2000-05-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding human interleukin-18 (IL-18, interferon-γ inducing factor)
JP3955352B2 (ja) * 1997-02-25 2007-08-08 株式会社林原生物化学研究所 破骨細胞形成阻害剤
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
JP2004514652A (ja) * 2000-06-02 2004-05-20 スミスクライン・ビーチャム・コーポレイション Ｉｌ−１８およびｉｌ−１８組み合わせを用いるウイルス疾患の治療法
AU2002324249B2 (en) * 2001-03-08 2007-04-05 Ares Trading S.A. Interleukin-18 mutants, their production and use
US20050153880A1 (en) * 2002-06-27 2005-07-14 Yukio Goto Methods of treating or preventing ibd with il-18
AU2003299919B2 (en) * 2002-10-08 2009-08-06 Ares Trading S.A. The use of cytokine able to bind IL-18BP and of inhibiting the activity of a second cytokine
DE602004025799D1 (de) * 2003-04-15 2010-04-15 Glaxosmithkline Llc Humane il-18 substitutionsmutanten und deren konjugate
ES2384241T3 (es) * 2003-05-13 2012-07-02 Merck Serono Sa Variantes activas de la proteína que fija IL-18 y usos médicos de las mismas
DK1648931T3 (da) * 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
WO2005075648A1 (en) * 2004-01-28 2005-08-18 Gifu University Interleukin-18 mutant proteins
JOP20200308A1 (ar) * 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins

Also Published As

Publication number Publication date
IL272635B1 (en) 2023-10-01
BR112020004389A2 (pt) 2020-09-08
IL272635A (en) 2020-03-31
US20190070262A1 (en) 2019-03-07
JP2023157959A (ja) 2023-10-26
CN111315395A (zh) 2020-06-19
US20230241172A1 (en) 2023-08-03
AU2018330444B2 (en) 2023-08-17
WO2019051015A1 (en) 2019-03-14
AU2023266285A1 (en) 2024-01-25
SG11202001384TA (en) 2020-03-30
AU2018330444A1 (en) 2020-04-23
US20230321192A1 (en) 2023-10-12
US20230355714A1 (en) 2023-11-09
CA3080492A1 (en) 2019-03-14
KR20200066623A (ko) 2020-06-10
EP3678681A4 (en) 2021-07-14
JP2020533301A (ja) 2020-11-19
IL272635B2 (en) 2024-02-01
IL305370A (en) 2023-10-01
RU2020112538A (ru) 2021-10-06
RU2020112538A3 (es) 2022-04-04
EP3678681A1 (en) 2020-07-15

Similar Documents

Publication Publication Date Title
MX2020002542A (es) Variantes de interleucina-18 y metodos de uso.
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
ZA201905488B (en) Tigit- and light-based chimeric proteins
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2019012431A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
MX2022004304A (es) Agentes inductores de apoptosis.
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2021013476A (es) Composiciones de pienso para animales y uso de las mismas.
TR201820333T4 (tr) Bakteri Suşları İçeren Bileşimler
MX2018009750A (es) Composiciones potenciadoras de vcn y métodos para su uso.
PH12016501107B1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
MX2023011657A (es) Composiciones que comprenden curones y usos de los mismos.
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2017014459A (es) Compuestos de tioeter como inhibidores de la nitrificacion.
ZA202000354B (en) Novel braf inhibitors and use thereof for treatment of cutaneous reactions
MX2019002185A (es) Composiciones y metodos relacionados con la inhibicion de la señalizacion de rangos.
MX2021006977A (es) Anellosomas y metodos de uso.